Related Experiment Video
Updated: Aug 19, 2025
Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer
Published on: September 8, 2023
Budget impact analysis of next-generation sequencing versus sequential single-gene testing in Japanese patients with
Hiroyuki Matsuda1, Toru Ogawa2, Yasunari Sadatsuki3
1Real World Evidence Solutions & HEOR, IQVIA Solutions Japan K.K., Tokyo, Japan.
Background:
Identification of genomic alterations (e.g., EGFR, ALK, ROS1, BRAF, NTRK, and MET) is essential for initiating targeted therapy in patients with advanced non-small-cell lung cancer (aNSCLC). This study estimated the budget impact of using the sequential single-gene (SSG) test, which tests for each mutation one at a time, versus next-generation sequencing (NGS), which tests for all mutations at the same time, among newly diagnosed patients with aNSCLC from a Japanese healthcare payer's perspective.
Methods:
A budget impact model (BIM) was used to determine the expected budget impact associated with NGS for newly diagnosed aNSCLC in Japan over a 3-year period. The BIM compared the total costs (biopsy, testing, and treatment) and average turnaround time of "future NGS" and "current NGS" versus SSG testing.
Results:
The adoption of current NGS over SSG testing had a budget impact of -0.24%, but adoption of future NGS over SSG testing had a budget impact of +4.33% across a 3-year time horizon on the Japanese budget for aNSCLC treatment. The adoption of current or future NGS over SSG testing would shorten the average turnaround time for testing.
Conclusions:
The adoption of current NGS over SSG testing would slightly decrease the yearly costs. However, the adoption of future or current NGS over SSG testing would shorten the average turnaround time, enabling faster identification of genomic alterations and earlier initiation of treatment for aNSCLC patients in Japan.
Insights
Next-generation sequencing (NGS) for advanced non-small-cell lung cancer (aNSCLC) in Japan offers faster genomic alteration identification and earlier treatment initiation. While current NGS slightly reduces costs, future NGS increases them, but both NGS approaches significantly shorten turnaround times compared to sequential single-gene testing.
Area of Science:
- Oncology
- Genomics
- Health Economics
Background:
- Genomic alterations (e.g., EGFR, ALK, ROS1, BRAF, NTRK, MET) are crucial for targeted therapy in advanced non-small-cell lung cancer (aNSCLC).
- Comparing sequential single-gene (SSG) testing with next-generation sequencing (NGS) is vital for optimizing treatment strategies.
Purpose of the Study:
- To estimate the budget impact of NGS versus SSG testing for newly diagnosed aNSCLC patients in Japan.
- To evaluate the cost-effectiveness and turnaround time differences between NGS and SSG testing from a healthcare payer's perspective.
Main Methods:
- A 3-year budget impact model (BIM) was developed for the Japanese healthcare system.
- The BIM compared total costs (biopsy, testing, treatment) and turnaround times for current NGS, future NGS, and SSG testing.
Main Results:
- Adoption of current NGS over SSG testing resulted in a -0.24% budget impact.
- Adoption of future NGS over SSG testing resulted in a +4.33% budget impact over 3 years.
- Both current and future NGS significantly reduced average testing turnaround times compared to SSG.
Conclusions:
- Current NGS adoption may slightly decrease yearly costs for aNSCLC treatment in Japan.
- NGS adoption, both current and future, accelerates genomic alteration identification, enabling earlier targeted therapy initiation for aNSCLC patients.
- Faster turnaround times with NGS are a key benefit for timely patient treatment.
More Related Videos
13:24Integration of Wet and Dry Bench Processes Optimizes Targeted Next-generation Sequencing of Low-quality and Low-quantity Tumor Biopsies
Published on: April 11, 2016
09:34Targeted Next-generation Sequencing and Bioinformatics Pipeline to Evaluate Genetic Determinants of Constitutional Disease
Published on: April 4, 2018
